The stock of CureVac N.V (CVAC) has gone down by -11.05% for the week, with a -10.41% drop in the past month and a -23.68% drop in the past quarter. The volatility ratio for the week is 6.47%, and the volatility levels for the past 30 days are 5.59% for CVAC. The simple moving average for the past 20 days is -8.96% for CVAC’s stock, with a -21.42% simple moving average for the past 200 days.
Is It Worth Investing in CureVac N.V (NASDAQ: CVAC) Right Now?
The price-to-earnings ratio for CureVac N.V (NASDAQ: CVAC) is 4.65x, which is above its average ratio. Moreover, the 36-month beta value for CVAC is 2.59. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 3 as “hold,” and 1 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CVAC is 93.63M and currently, short sellers hold a 4.87% of that float. On November 15, 2024, CVAC’s average trading volume was 457.31K shares.
CVAC) stock’s latest price update
The stock of CureVac N.V (NASDAQ: CVAC) has decreased by -5.38 when compared to last closing price of 2.67.Despite this, the company has seen a loss of -11.05% in its stock price over the last five trading days. seekingalpha.com reported 2024-11-12 that CureVac N.V. (NASDAQ:CVAC ) Q3 2024 Earnings Conference Call November 12, 2024 9:00 AM ET Company Participants Sarah Fakih – Vice President of Corporate Communications and Investor Relations Alexander Zehnder – Chief Executive Officer Axel Malkomes – Chief Financial Officer Myriam Mendila – Chief Development Officer Rudiger Wolff – Senior Vice President of Finance Conference Call Participants Charlie Yang – Bank of America Merrill Lynch CJ Yeh – Leerink Partners Roy Buchanan – Citizens JMP Operator Greetings and welcome to the CureVac Financial Results and Business Update for the Third Quarter and First Nine Months of 2024 Conference Call.
Analysts’ Opinion of CVAC
Many brokerage firms have already submitted their reports for CVAC stocks, with Leerink Partners repeating the rating for CVAC by listing it as a “Market Perform.” The predicted price for CVAC in the upcoming period, according to Leerink Partners is $4 based on the research report published on April 25, 2024 of the current year 2024.
SVB Securities, on the other hand, stated in their research note that they expect to see CVAC reach a price target of $13. The rating they have provided for CVAC stocks is “Outperform” according to the report published on June 08th, 2023.
UBS gave a rating of “Buy” to CVAC, setting the target price at $18 in the report published on January 19th of the previous year.
CVAC Trading at -13.65% from the 50-Day Moving Average
After a stumble in the market that brought CVAC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.90% of loss for the given period.
Volatility was left at 5.59%, however, over the last 30 days, the volatility rate increased by 6.47%, as shares sank -10.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.21% lower at present.
During the last 5 trading sessions, CVAC fell by -11.44%, which changed the moving average for the period of 200-days by -29.75% in comparison to the 20-day moving average, which settled at $2.77. In addition, CureVac N.V saw -39.99% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CVAC starting from Pierre Kemula, who proposed sale 55 shares at the price of $3.08 back on Sep 27 ’24. After this action, Pierre Kemula now owns shares of CureVac N.V, valued at $169 using the latest closing price.
Pierre Kemula, the affiliate of CureVac N.V, proposed sale 34,000 shares at $3.10 during a trade that took place back on Sep 25 ’24, which means that Pierre Kemula is holding shares at $105,400 based on the most recent closing price.
Stock Fundamentals for CVAC
Current profitability levels for the company are sitting at:
- -4.46 for the present operating margin
- -1.55 for the gross margin
The net margin for CureVac N.V stands at -4.23. The total capital return value is set at -0.65. Equity return is now at value 17.08, with 13.38 for asset returns.
Currently, EBITDA for the company is -234.09 million with net debt to EBITDA at 0.63. When we switch over and look at the enterprise to sales, we see a ratio of 5.81. The receivables turnover for the company is 2.71for trailing twelve months and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.20.
Conclusion
To wrap up, the performance of CureVac N.V (CVAC) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
